Note: This document contains side effect information about rabeprazole. Some dosage forms listed on this page may not apply to the brand name Aciphex Sprinkle.
Applies to rabeprazole: oral tablets.
Side effects include:
Pain, pharyngitis, flatulence, infection, constipation.
For Healthcare Professionals
Applies to rabeprazole: oral delayed release capsule, oral delayed release tablet, oral tablet extended release.
General
The most commonly reported side effects are headache, diarrhea, and abdominal pain.[Ref]
Gastrointestinal
Very common (10% or more): Diarrhea (up to 21%), abdominal pain (up to 16%), vomiting (up to 14%)
Common (1% to 10%): Benign fundic gland polyps, constipation, flatulence, nausea
Uncommon (0.1% to 1%): Dry mouth, dyspepsia, eructation
Rare (0.01% to 0.1%): Gastritis, stomatitis
Frequency not reported: Microscopic colitis
Postmarketing reports: Clostridium difficile-associated diarrhea[Ref]
Other
Common (1% to 10%): Asthenia, non-specific pain, pain
Uncommon (0.1% to 1%): Chills, pyrexia/fever
Postmarketing reports: Sudden death[Ref]
Respiratory
Common (1% to 10%): Cough, pharyngitis, rhinitis
Uncommon (0.1% to 1%): Bronchitis, sinusitis
Postmarketing reports: Dyspnea, interstitial pneumonia[Ref]
Nervous system
Hepatic encephalopathy occurred in patients with underlying cirrhosis.[Ref]
Common (1% to 10%): Dizziness, headache, taste disturbance/perversion
Uncommon (0.1% to 1%): Somnolence
Rare (0.01% to 0.1%): Hepatic encephalopathy
Postmarketing reports: Coma, vertigo[Ref]
Immunologic
Common (1% to 10%): Flu-like syndrome/ influenza-like illness, infection[Ref]
Musculoskeletal
Common (1% to 10%): Back pain, myalgia
Uncommon (0.1% to 1%): Arthralgia, fracture of hip/wrist/spine, leg cramps
Postmarketing reports: Bone fractures, rhabdomyolysis[Ref]
Dermatologic
Erythema and bullous reactions usually resolved after discontinuation.[Ref]
Common (1% to 10%): Rash
Uncommon (0.1% to 1%): Erythema
Rare (0.01% to 0.1%): Bullous reactions, pruritus, sweating
Very rare (less than 0.01%): Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)
Frequency not reported: Facial swelling, subacute cutaneous lupus erythematosus
Postmarketing reports: fatal TEN, other drug eruptions, severe dermatological reactions, systemic lupus erythematosus, urticarial skin eruptions[Ref]
Psychiatric
Common (1% to 10%): Insomnia
Uncommon (0.1% to 1%): Nervousness
Rare (0.01% to 0.1%): Depression
Frequency not reported: Confusion
Postmarketing reports: Delirium, disorientation[Ref]
Cardiovascular
Common (1% to 10%): Chest pain
Uncommon (0.1% to 1%): Peripheral edema
Postmarketing reports: Hypotension[Ref]
Hepatic
Uncommon (0.1% to 1%): Increased hepatic enzymes
Rare (0.01% to 0.1%): Hepatitis, jaundice, serious hepatic dysfunction[Ref]
Increased hepatic enzymes occurred in patients with underlying cirrhosis.[Ref]
Genitourinary
Uncommon (0.1% to 1%): Urinary tract infection[Ref]
Hematologic
Rare (0.01% to 0.1%): Leukocytosis, leukopenia, neutropenia, thrombocytopenia
Postmarketing reports: Agranulocytosis, bicytopenia, blood dyscrasias, hemolytic anemia, increase in prothrombin time/INR, pancytopenia[Ref]
Increased prothrombin time/INR occurred in patients taking warfarin concomitantly.[Ref]
Metabolic
Rare (0.01% to 0.1%): Anorexia, weight gain
Frequency not reported: Cyanocobalamin (Vitamin B-12) deficiency, hypomagnesemia, hyponatremia
Postmarketing reports: Hyperammonemia[Ref]
Renal
Rare (0.01% to 0.1%): Interstitial nephritis[Ref]
Ocular
Rare (0.01% to 0.1%): Visual disturbance
Postmarketing reports: Blurred vision[Ref]
Endocrine
Frequency not reported: Gynecomastia
Postmarketing reports: Thyroid stimulating hormone (TSH) elevations[Ref]
Hypersensitivity
Hypersensitivity reactions included facial swelling, hypotension, dyspnea, erythema, and bullous reactions; these reactions typically resolved after discontinuation.[Ref]
Rare (0.01% to 0.1%): Hypersensitivity
Postmarketing reports: Acute systemic allergic reactions, anaphylaxis/anaphylactic reactions, angioedema, potential allergic reactions[Ref]
